Clinical Trial Update: A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating three oral doses of laquinimod in Huntington's disease has been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Laquinimod (laquinimod)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Huntington's Disease | Phase 2 | Status: COMPLETED | Results posted: 2019-06-19